Investors pull away from Upstream as a twice-yearly dose of verekitug fails to match Tezspire’s efficacy in reducing asthma exacerbations.

Shares of Upstream Bio crashed Wednesday after the biotech's asthma drug succeeded in Phase 2 study, but with a more frequent dosing regimen.

Upstream Bio, Inc. downgraded despite strong Verekitug phase 2 asthma results; assess anti-TSLP competition, dosing edge & catalysts. Click for this UPB update.

Investing.com -- Upstream Bio (NASDAQ:UPB) stock fell 23% after the company reported mixed results from its Phase 2 VALIANT trial of verekitug for severe asthma treatment.

On Thursday, Tevogen Bio Holdings Inc. (NASDAQ:TVGN) announced its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative 5-year ...

Nuvation Bio enrolled the first patient in a late-stage study of Ibtrozi. The bigger story, though, was a Wall Street analyst's initiation of coverage on the stock. Shares of Nuvation Bio (NYSE: NUVB) ...